Latest long-term debt for CRVS: $270K.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2026), CRVS shows a long-term debt of $270K. That compares with $730K in the prior-year period — down 62.4% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, CRVS's long-term debt is now $270K (was $730K) — a 62.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Corvus Pharmaceuticals is outperforming or lagging.
Tracking CRVS's long-term debt over time shows whether Corvus Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $270K That compares with $730K in the prior-year period — down 62.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has Corvus Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $270K) with ownership activity and broader fundamentals.
Corvus Pharmaceuticals's long-term debt is $270K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.